Facetten
Zugriff
Einrichtung
Medientyp
- Text 13
Karte
Erscheinungsjahr
Autor/in
- Hadji, Peyman
- Hartkopf, Andreas D
- Tesch, Hans 11
- Häberle, Lothar 9
- Kolberg, Hans-Christian 9
- alle zeigen
Sprache
13 Einträge gefunden
-
Return of individual genomic research results within the PRAEGNANT multicenter registry study
- Huebner, Hanna
- Ruebner, Matthias
- Kurbacher, Christian
- Hadji, Peyman
- Hartkopf, Andreas D
- Lux, Michael P
- Huober, Jens
-
Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients - Data from the Real-World Registry PRAEGNANT
- Engler, Tobias
- Fasching, Peter A
- Lüftner, Diana
- Hartkopf, Andreas D
- Müller, Volkmar
- Kolberg, Hans-Christian
- Hadji, Peyman
-
Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics - A retrospective analysis of a real world registry
- Müller, Volkmar
- Hein, Alexander
- Hartkopf, Andreas D
- Fasching, Peter A
- Kolberg, Hans-Christian
- Hadji, Peyman
- Tesch, Hans
-
Corrigendum to "Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany"
- Schneeweiss, Andreas
- Ettl, Johannes
- Lüftner, Diana
- Beckmann, Matthias W
- Belleville, Erik
- Fasching, Peter A
- Fehm, Tanja N
-
-
Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab
- Michel, Laura L
- Hartkopf, Andreas D
- Fasching, Peter A
- Kolberg, Hans-Christian
- Hadji, Peyman
- Tesch, Hans
- Häberle, Lothar
-
Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany
- Schneeweiss, Andreas
- Ettl, Johannes
- Lüftner, Diana
- Beckmann, Matthias W
- Belleville, Erik
- Fasching, Peter A
- Fehm, Tanja N
-
Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry
- Hartkopf, Andreas D
- Huober, Jens
- Volz, Bernhard
- Nabieva, Naiba
- Taran, Florin-Andrei
- Schwitulla, Judith
- Overkamp, Friedrich
-
Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry
- Müller, Volkmar
- Nabieva, Naiba
- Häberle, Lothar
- Taran, Florin-Andrei
- Hartkopf, Andreas D
- Volz, Bernhard
- Overkamp, Friedrich
-
Update Breast Cancer 2018 (Part 1) - Primary Breast Cancer and Biomarkers
- Taran, Florin-Andrei
- Schneeweiss, Andreas
- Lux, Michael P
- Janni, Wolfgang
- Hartkopf, Andreas D
- Nabieva, Naiba
- Overkamp, Friedrich
-
-
Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry
- Lux, Michael P
- Nabieva, Naiba
- Hartkopf, Andreas D
- Huober, Jens
- Volz, Bernhard
- Taran, Florin-Andrei
- Overkamp, Friedrich
-
Update Breast Cancer 2017 - Implementation of Novel Therapies
- Lux, Michael P
- Janni, Wolfgang
- Hartkopf, Andreas D
- Nabieva, Naiba
- Taran, Florin-Andrei
- Overkamp, Friedrich
- Kolberg, Hans-Christian